This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Reta - GLP-3
Investigational Multi-Agonist Peptide
/WHAT_IT_IS
Reta GLP-3 is a triple agonist targeting GLP-1, GIP, and glucagon receptors, being explored for its powerful metabolic effects, especially in obesity and type 2 diabetes.
/USAGE
Used in clinical trials and investigational studies for significant body fat reduction, appetite control, and glucose management.
/MECHANISM_OF_ACTION
Acts on GLP-1, GIP, and glucagon receptors to enhance insulin sensitivity, reduce appetite, and increase energy expenditure.
Reported Benefits
- +Substantial weight loss
- +Improved glycemic control
- +Enhanced metabolic rate
Reported Side Effects
- −Nausea
- −Gastrointestinal discomfort
- −Possible increased heart rate
/STACKED_WITH
/RESEARCH_NOTES
Considered one of the most promising peptides in obesity research. Still under investigation in Phase II/III trials.
/REFERENCE
https://www.nature.com/articles/s41421-024-00700-0/RELATED
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.